Aptevo Therapeutics Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted asset value: $5.59M net cash (haircut ~50% for near-term going-concern/dilution risk given -$26.51M TTM net loss against a small cash balance) plus an estimated $2.0M NPV for existing IXINITY/royalty-bearing product and licensing assets; total ~$4.8M; 1.80M shares.

Reasoning: Aptevo is a micro-cap biotech with an existing commercial/royalty product alongside a loss-making pipeline, so a heavily risk-adjusted blend of net cash and residual product/royalty value is more appropriate than a going-concern FCF DCF given the severe cash burn relative to its balance sheet.